{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:28:56Z","timestamp":1770287336351,"version":"3.49.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.urolonc.2015.05.030","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T08:12:23Z","timestamp":1435911143000},"page":"464-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms"],"prefix":"10.1016","volume":"33","author":[{"given":"\u00c5sa","family":"Tivesten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehonathan H.","family":"Pinthus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelmina","family":"Duivenvoorden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2015.05.030_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","article-title":"Side effects of androgen deprivation therapy: monitoring and minimizing toxicity","volume":"61","author":"Higano","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2015.05.030_bib2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1464-410X.2008.07933.x","article-title":"Metabolic and cardiovascular effects of androgen deprivation therapy","volume":"102","author":"Hakimian","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.05.030_bib3","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.juro.2009.01.047","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"181","author":"Saylor","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2164\/jandrol.108.005454","article-title":"Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth","volume":"29","author":"Basaria","year":"2008","journal-title":"J Androl"},{"key":"10.1016\/j.urolonc.2015.05.030_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clon.2008.11.013","article-title":"Metabolic syndrome and prostate cancer: a review","volume":"21","author":"Nobes","year":"2009","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.urolonc.2015.05.030_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2015.05.030_bib7","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib8","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","article-title":"Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer","volume":"60","author":"Azoulay","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib9","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study","volume":"65","author":"Jespersen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib11","first-page":"1011","article-title":"Treatment and survival of patients with cancer of the prostate","volume":"124","author":"The Veterans Administration Co-operative Urological Research Group","year":"1967","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.urolonc.2015.05.030_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO;2-9","article-title":"Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo","volume":"26","author":"Bailar","year":"1970","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2015.05.030_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(13)70025-1","article-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)","volume":"14","author":"Langley","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib14","first-page":"18","article-title":"LHRH agonists versus GnRH antagonists for the treatment of prostate cancer","volume":"4","author":"Van Poppel","year":"2010","journal-title":"Belgian J Med Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib15","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2015.05.030_bib16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2015.05.030_bib17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","article-title":"Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism","volume":"61","author":"Hu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib18","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1111\/bju.12732","article-title":"The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study","volume":"114","author":"Gandaglia","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.05.030_bib19","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib20","doi-asserted-by":"crossref","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2015.05.030_bib21","doi-asserted-by":"crossref","unstructured":"Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2014, http:\/\/dx.doi.org\/10.1016\/j.eururo.2014.11.039 [Epub ahead of print].","DOI":"10.1016\/j.eururo.2014.11.039"},{"key":"10.1016\/j.urolonc.2015.05.030_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000334999","article-title":"Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term","volume":"82","author":"Wilcox","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.urolonc.2015.05.030_bib25","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2015.05.030_bib26","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication, Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm229986.htm; 2010 [accessed 08.14]."},{"key":"10.1016\/j.urolonc.2015.05.030_bib27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2015.05.030_bib28","unstructured":"Health Canada, Available from: http:\/\/www.healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2011\/13541a-eng.php; 2011. [accessed 08.14]."},{"key":"10.1016\/j.urolonc.2015.05.030_bib29","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. EAU prostate cancer clinical guidelines, http:\/\/www.uroweb.org\/guidelines\/online-guidelines\/; 2013 [accessed 08.14]"},{"key":"10.1016\/j.urolonc.2015.05.030_bib30","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.05.030_bib31","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","article-title":"Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib32","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","article-title":"Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix","volume":"186","author":"Smith","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib34","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D\u2019Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib35","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1592\/phco.28.12.1511","article-title":"Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer","volume":"28","author":"Kintzel","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.urolonc.2015.05.030_bib36","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2015.05.030_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1464-410X.2010.09273.x","article-title":"Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke","volume":"106","author":"Hayes","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.05.030_bib38","article-title":"Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","author":"Ziehr","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.05.030_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.09.008","article-title":"The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy","volume":"86","author":"Conteduca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2015.05.030_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2008.09.004","article-title":"Management of complications of androgen deprivation therapy in the older man","volume":"70","author":"Mohile","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib42","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2011.07.019","article-title":"High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden","volume":"58","author":"Ohlsson","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib43","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis","volume":"96","author":"Araujo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2015.05.030_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1530\/EJE-11-0447","article-title":"Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study","volume":"165","author":"Corona","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib45","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1210\/en.2010-0663","article-title":"Androgen receptor-dependent and independent atheroprotection by testosterone in male mice","volume":"151","author":"Bourghardt","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.urolonc.2015.05.030_bib46","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/JOE-12-0582","article-title":"Testosterone: a vascular hormone in health and disease","volume":"217","author":"Kelly","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib47","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0006-291X(02)02038-7","article-title":"Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages","volume":"296","author":"Langer","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.urolonc.2015.05.030_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2015.05.030_bib49","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2015.05.030_bib50","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2015.05.030_bib51","unstructured":"Endocrine Society, https:\/\/www.endocrine.org\/membership\/email-newsletters\/endocrine-insider\/2014\/february-20-2014\/; 2014 [accessed 08.14]"},{"key":"10.1016\/j.urolonc.2015.05.030_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MED.0b013e3283394e20","article-title":"Androgens, angiogenesis and cardiovascular regeneration","volume":"17","author":"Sieveking","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.urolonc.2015.05.030_bib53","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.ATV.0000178991.71605.18","article-title":"Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage","volume":"25","author":"Virmani","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1161\/CIRCULATIONAHA.113.001533","article-title":"Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling","volume":"128","author":"Yoshida","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2015.05.030_bib55","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1161\/01.CIR.91.11.2742","article-title":"Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses","volume":"91","author":"Ajayi","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2015.05.030_bib56","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1084\/jem.20082521","article-title":"Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor","volume":"206","author":"Chuang","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.urolonc.2015.05.030_bib57","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jacc.2005.02.054","article-title":"Which white blood cell subtypes predict increased cardiovascular risk?","volume":"45","author":"Horne","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2249.2005.02904.x","article-title":"GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males","volume":"142","author":"Tanriverdi","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib59","doi-asserted-by":"crossref","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","article-title":"Pathology of the vulnerable plaque","volume":"47","author":"Virmani","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib60","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.ATV.11.5.1223","article-title":"Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells","volume":"11","author":"Amento","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.urolonc.2015.05.030_bib61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.ATV.16.1.19","article-title":"Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta","volume":"16","author":"Geng","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib62","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/j.1582-4934.2010.01121.x","article-title":"Macrophages heterogeneity in atherosclerosis - implications for therapy","volume":"14","author":"Wilson","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.urolonc.2015.05.030_bib63","doi-asserted-by":"crossref","first-page":"e8852","DOI":"10.1371\/journal.pone.0008852","article-title":"Macrophage plasticity in experimental atherosclerosis","volume":"5","author":"Khallou-Laschet","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2015.05.030_bib64","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.urolonc.2014.06.018","article-title":"GnRH-antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared to orchiectomy and GnRH-agonist in a preclinical mouse model","volume":"32","author":"Hopmans","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib65","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/eurheartj\/ehs411","article-title":"Update on acute coronary syndromes: the pathologists\u2019 view","volume":"34","author":"Falk","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.urolonc.2015.05.030_bib66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.8755-8920.2000.440307.x","article-title":"Immunoidentification of gonadotropin releasing hormone receptor in human sperm, pituitary and cancer cells","volume":"44","author":"Lee","year":"2000","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib67","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/pros.1072","article-title":"Gonadotropin-releasing hormone receptor expression in the human prostate","volume":"47","author":"Tieva","year":"2001","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2015.05.030_bib68","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2826.2011.02119.x","article-title":"The heart: a novel gonadotrophin-releasing hormone target","volume":"23","author":"Dong","year":"2011","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0304-3835(06)80010-8","article-title":"Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues","volume":"98","author":"Kakar","year":"1995","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2015.05.030_bib70","first-page":"22","article-title":"The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix","author":"Garnick","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib71","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1073\/pnas.0400782101","article-title":"A gene atlas of the mouse and human protein-encoding transcriptomes","volume":"101","author":"Su","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2015.05.030_bib72","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/bi952290f","article-title":"receptor monoclonal antibodies: immunochemical and immunocytochemical characterization of the receptor","volume":"35","author":"Vannier","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.urolonc.2015.05.030_bib73","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1001283","article-title":"Expression of follicle-stimulating hormone receptor in tumor blood vessels","volume":"363","author":"Radu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2015.05.030_bib74","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/jcem-66-2-308","article-title":"Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy","volume":"66","author":"Huhtaniemi","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2015.05.030_bib75","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.urolonc.2015.05.030_bib76","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2015.05.030_bib77","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","article-title":"A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy","volume":"109","author":"Nobes","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.05.030_bib78","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.13.5517","article-title":"Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib79","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.030_bib80","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143915002744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143915002744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:05:55Z","timestamp":1761041155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143915002744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1078143915002744"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2015.05.030","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2015.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}